Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes

作者：Shieh Shwn Huey; Probst Janice C; Sung Fung Chang; Tsai Wen Chen; Li Ya Shin; Chen Chih Yi^*

来源：BMC Cancer, 2012, 12(1): 174.

DOI：10.1186/1471-2407-12-174

• Lung cancer
• Comorbidity
• Diabetes
• Survival
• Tuberculosis

Background: Comorbid conditions influence the survival of cancer patients. This study evaluated the influence of comorbidity on survival among lung cancer patients. %26lt;br%26gt;Methods: The authors evaluated the medical records of 1111 lung cancer patients of a medical center in Taiwan. Days of survival were calculated for each patient and mortality hazard ratios were estimated for associations with demographic status, comorbidity and cancer stage at diagnosis. %26lt;br%26gt;Results: On average, the survival time was slightly longer among women than among men (838 +/- 689 vs. 749 +/- 654 days, p = 0.050). Survival days increased with age (from 580 +/- 526 [%26lt;= 50 years] to 803 +/- 693 [%26gt;= 71 years] days, p = 0.020) and decreased with stage (from 1224 +/- 656 [stage I] to 489 +/- 536 [stage IV] days, p %26lt; 0.001). Younger patients were more likely to be diagnosed with lung cancer at a late stage. Compared with lung cancer patients without tuberculosis, those with tuberculosis had a significantly shorter average survival duration (584 vs. 791 days, p = 0.002) and a higher mortality hazard ratio (1.30, 95% CI: 1.03 - 1.65). A similar trend was observed in lung cancer patients with diabetes. %26lt;br%26gt;Conclusions: Lung cancer patients with comorbid tuberculosis or diabetes are at an elevated risk of mortality. These patients deserve greater attention while undergoing cancer treatment.

• 出版日期2012-5-11
• 单位中国医科大学